Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) Equity Average (2016 - 2025)

Northwest Biotherapeutics' Equity Average history spans 15 years, with the latest figure at -$84.5 million for Q4 2025.

  • Quarterly results put Equity Average at -$84.5 million for Q4 2025, up 3.25% from a year ago — trailing twelve months through Dec 2025 was -$84.5 million (up 3.25% YoY), and the annual figure for FY2025 was -$77.4 million, up 3.43%.
  • Equity Average for Q4 2025 was -$84.5 million at Northwest Biotherapeutics, up from -$104.5 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of -$58.5 million in Q2 2023 to a low of -$358.1 million in Q1 2021.
  • The 5-year median for Equity Average is -$98.5 million (2025), against an average of -$133.8 million.
  • The sharpest move saw Equity Average plummeted 777.26% in 2021, then skyrocketed 69.82% in 2022.
  • Year by year, Equity Average stood at -$212.9 million in 2021, then soared by 44.34% to -$118.5 million in 2022, then soared by 42.67% to -$67.9 million in 2023, then dropped by 28.54% to -$87.3 million in 2024, then grew by 3.25% to -$84.5 million in 2025.
  • According to Business Quant data, Equity Average over the past three periods came in at -$84.5 million, -$104.5 million, and -$99.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.